Neurotherapeutics in the Era of Translational Medicine

Herausgegeben:Smith, Richard A.; Kaspar, Brian K.; Svendsen, Clive N.

• Broschiertes Buch

Produktbeschreibung

For the first time in history, there is now hope for treating neurological disorders that had previously been considered untreatable. The remarkable confluence of events that has heralded this is the focus of Neurotherapeutics in the Era of Translational Medicine. This anthology, written by many of the prominent scientists and researchers in the field of biotechnology, recounts the breathtaking advances that are revolutionizing treatment for disorders such as amyotrophic lateral sclerosis?, spinal muscular atrophy, multiple sclerosis, Parkinson's disease, myasthenia gravis, migraine, and glioblastoma. The "story behind the story" of these translational efforts is told, with authors depicting the ups and downs encountered on the path of their drug discovery and development effort. In parallel with this path, advances in identifying novel biomarkers and disease models are summarized, as are contemporary issues focusing on clinical trial design, bioethics, innovative funding strategies, and collaborations between government and academia in an effort to facilitate breakthrough treatments. The book is written by members of the biotech and pharmaceutical ecosystem for those who belong to it and aspire to become part of it.

Produktdetails

• Verlag: Academic Press / Elsevier Science & Technology
• Artikelnr. des Verlages: C2018-0-00588-5
• Seitenzahl: 518
• Erscheinungstermin: 4. Dezember 2020
• Englisch
• Abmessung: 234mm x 190mm
• Gewicht: 1090g
• ISBN-13: 9780128164754
• ISBN-10: 0128164751
• Artikelnr.: 58261993

Inhaltsangabe

1. Development of a molecular therapy for the SOD1 familial variant of ALS
2. Unraveling molecular biology of C9ORF72 repeat expansions in amyotrophic lateral sclerosis-frontotemporal dementia: Implications for therapy
3. Translating molecular therapies for spinal muscular atrophy
4. From uncovering the mechanism of transthyretin aggregation to the drug tafamidis for ameliorating neurodegeneration and cardiomyopathy
5. A novel treatment for Parkinson's disease and ALS: Combined cell
and gene therapies
6. Parkinson's disease: Genetic-driven therapeutic approaches
7. Neural stem cell-mediated brain tumor therapy
8. Advances in migraine therapeutics: The role of calcitonin
gene-related peptide
9. The impact of translational research on the development of therapeutic
agents for multiple sclerosis
10. Advances in treating myasthenia gravis
11. The endocannabinoid system as a target for the treatment
of neurological disorders
12. Identification of biomarkers for diagnosing and monitoring therapy in the treatment of neurologic disorders
13. 3D Alzheimer's disease in a dish: Implications for drug discovery
14. Improving clinical trial efficiency with machine learning models
of disease progression
15. Positron emission tomography imaging agents for evaluating the pathologic features of Alzheimer's disease and drug development
16. Repurposing FDA-approved pharmaceuticals: The development
of Nuedexta
17. Bioethics in the era of translational medicine
18. Government efforts to promote the development of neurotherapeutics for the treatment of neurological diseases
19. Innovative funding models for neurotherapeutics

Rezensionen

"Overall, this is a wonderful book for those interested in or familiar with neuroscience, neurological disease, and biotechnology, who wish to have a historical context while learning about the development of novel neurotherapeutic agents. There are few books that cover such a breadth and depth as this one does. It is quite helpful for its intended audience and does the subject justice. It is a worthy addition to any clinician-scientist's library." --© Doody Review, 2020, Ali A Saherwala, MD, reviewer, expert opinion